Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Podcasts » ATS guidelines in COPD: When is one therapy not enough?
International Journal of Chronic Obstructive Pulmonary Disease
ATS guidelines in COPD: When is one therapy not enough?
Filetype: MP3 - Size: 50.4MB - Duration: 22:02mins
Dr Richard Russell and Professor Michael Dreher present the 2020 American Thoracic Society Guidelines on the management of COPD,1 to which Professor Dreher was a key contributor. Listen as the experts deliberate on the use of dual bronchodilation and inhaled corticosteroids in patients with COPD, as well as reviewing conditional and strong recommendations for treatment, according to the guidelines.1,2 Dr Russell will also discuss the findings of a publication about maintenance inhaler therapy preferences of patients with COPD.3 Finally, Dr Russell will delve into the social media hot topic of air pollution and the effects it can have on patients with COPD.
1 Nici L, et al. Am J Respir Crit Care Med 2020;201:e56–e69;
2 Global Initiative for Chronic Obstructive Lung Disease. Updated 2022. Available at: https://goldcopd.org/wp-content/uploads/2021/11/GOLD-REPORT-2022-v1.0-12Nov2021_WMV.pdf. Last accessed: November 2021;
3 Tervonen T, et al. Thorax 2020;75:735–743
Professor Michael Dreher reports speaker fees from Actelion Pharmaceuticals, AstraZeneca, Bayer, Berlin-Chemie, Boehringer Ingelheim, Chiesi, Hamilton, Heinen und Löwenstein, Linde, Novartis, Pfizer, Philips Respironics, ResMed, Roche and Weinmann. He also reports consulting fees from Almirall, Boehringer Ingelheim, Linde, Novartis, Pfizer, Philips Respironics, ResMed and Roche, and research grants from Linde, Philips Respironics and ResMed.
Professor Michael Dreher
Download transcript: here
Published on: 15 December 2021